Skip to search formSkip to main contentSkip to account menu

RSD 1235

Known as: RSD-1235, RSD1235 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

vernakalant

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Meta-analysis of effect of vernakalant on conversion of atrial fibrillation
BackgroundIn recent years, there has been a large amount of studies about the efficacy and safety of vernakalant or RSD1235, an… 
2012
2012
Late development of pulmonary arterial hypertension after arterial switch for transposition of the great arteries.
2009
2009
Pharmacokinetics of Novel Atrial‐Selective Antiarrhythmic Agent Vernakalant Hydrochloride Injection (RSD1235): Influence of CYP2D6 Expression and Other Factors
Vernakalant hydrochloride injection (RSD1235) is a relatively atrial‐selective antiarrhythmic agent that converts atrial… 
2009
2009
Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels.
Review
2008
Review
2008
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
Highly Cited
2007
Highly Cited
2007
The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans
Objectives: To determine the acute effects of vernakalant (RSD1235) on electrophysiologic (EP) properties in humans. Background… 
2006
2006
148: RSD1235 Effectively Converts Acute Atrial Fibrillation to Sinus Rhythm Independent of Background Use of Oral Rate- or Rhythm-Control Medications
2006
2006
Abstract 3697: RSD1235 Effectively Converts Atrial Fibrillation to Sinus Rhythm Independent of Background Use of Oral Rate- or Rhythm-Control Medications
2005
2005
RSD1235 in the Treatment of Recent Onset Atrial Fibrillation in ACT I, (Atrial Arrhythmia Conversion Trial I) - Effect of Age, Sex, and Prior Rate Control Medications
Review
2003
Review
2003
RSD-1235. Cardiome.
RSD-1235 is a novel, mixed ion channel antagonist in development by Cardiome Pharma for the potential treatment of heart… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)